Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reports a case where the IOP-lowering drug bimatoprost was associated with eyelash hypertrichosis.

This review explored the new and emerging treatments for androgenetic alopecia and alopecia areata, finding that JAK inhibitors show promise for alopecia areata, while advancements in stem-cell research may eventually lead to new and improved treatments for androgenetic alopecia.

This meta-analysis found that topical prostaglandin analogs could significantly improve hair length and density in patients with hair loss, compared to placebo, without notable safety differences.

This case report highlights a rare side effect of prostaglandin analogues, detailing prostaglandin-associated periorbitopathy in three glaucoma patients treated with bimatoprost and travoprost.

This study found that a cocktail of three proteins from embryonic skin can enable adult fibroblasts to regenerate hair follicles by altering gene expression and activating regenerative signaling pathways.

This study found that RCS-01 cell therapy for aged skin was well tolerated and associated with increased gene expression related to extracellular matrix homeostasis, suggesting potential skin improvement.

This article contains no new research findings or results.

This review highlights the clinical usefulness of bimatoprost in lowering intraocular pressure for glaucoma patients and its promising results in promoting hair growth for conditions like alopecia, with research also exploring potential new applications and delivery systems.

This abstract discusses the FDA approval of Latisse (bimatoprost) for increasing eyelash growth in patients with eyelash hypotrichosis and highlights its efficacy while noting unresolved effectiveness in certain conditions and potential side effects.

This article reviews the usage, efficacy, side effects, and alternatives of topical bimatoprost 0.03% for dermatological applications but does not present new clinical findings.

This study reports that applying bimatoprost ophthalmic solution 0.03% to the upper eyelid margin enhances eyelash growth by increasing length, thickness, and darkness, with a favorable safety profile.

This review discusses the cutaneous application of bimatoprost ophthalmic solution 0.03% for enhancing upper eyelash growth and suggests it is both safe and effective; no new clinical results are reported.

This study found that topical bimatoprost significantly improved eyelash growth in individuals with idiopathic and chemotherapy-induced eyelash hypotrichosis compared to a vehicle treatment.

In this study, daily application of bimatoprost 0.03% ophthalmic solution for 9 months significantly improved eyebrow appearance in individuals with mild to moderate eyebrow hypotrichosis, without observed side effects.

In this study, once-daily treatment with bimatoprost 0.03% solution significantly increased eyelash growth, thickness, and darkness in patients with chemotherapy-induced eyelash loss compared to placebo, and was well tolerated over one year.

The study found that daily use of bimatoprost ophthalmic solution 0.03% for one year was effective in improving eyelash growth and patient satisfaction in both idiopathic and chemotherapy-induced hypotrichosis, with no serious drug-related adverse events reported.

In this case report, a 60-year-old woman with eyebrow hypotrichosis experienced significant and lasting eyebrow growth after daily use of bimatoprost 0.03% solution, highlighting its potential as an effective treatment for eyebrow hair restoration.

This case report describes a patient with glaucoma who developed reversible hyperpigmentation and hypertrichosis after using bimatoprost eye drops, aiming to explore prostaglandin analogues' potential roles in hair and depigmentation therapies.

Bimatoprost gel makes eyelashes grow longer, but may cause side effects and should be monitored by an eye doctor.

This study found that prototype right heart circulatory assist devices significantly improved hemodynamics and reduced pulmonary vascular resistances in piglet models of acute hemodynamic shock.

This pilot study evaluated bimatoprost ophthalmic solution 0.03% for eyebrow hair regrowth in ten female patients, but reports no new clinical results.

This review examines the potential of bimatoprost for treating various types of eyelash and eyebrow hypotrichosis, discussing its pharmacological properties but providing no new clinical results.

This article reviews the use of bimatoprost for eyelash hypotrichosis and reports its effectiveness in promoting eyelash growth but highlights uncertain efficacy in cases of eyelash alopecia areata.

This case report suggests that topical bimatoprost may promote eyebrow hair growth, as observed in a patient with eyebrow hypotrichosis, but lacks broader published scientific evidence.

In this study, bimatoprost 0.03% was effective and well-tolerated for improving eyelash hypotrichosis in healthy adolescents, but not for those with the condition due to chemotherapy or alopecia areata.

This source reports that bimatoprost, a medication approved for eyelash growth, has shown efficacy in treating eyebrow hypotrichosis, suggesting it as a noninvasive, effective, and well-tolerated option for enhancing eyebrow hair.

In this randomized trial, bimatoprost 0.01% significantly improved eyebrow hair density and diameter in patients with eyebrow hypotrichosis compared to a placebo, with minimal adverse effects, suggesting it is an effective and safe treatment option.

In this 1-year study of patients with alopecia areata universalis, researchers found that 0.03% topical bimatoprost led to an acceptable cosmetic response in 43.24% of participants.